Fig. 5
From: Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin
Bortezomib-resistant cells are highly sensitive to RHM. A. Left panel: Cell viability of AMO1 and ABZB, treated with vehicle or increasing dose of RHM for 5 days. Middle panel: Annexin V assay of AMO1 and ABZB, treated with vehicle or RHM (5 μM) for 48 h. Right panel: Immunoblot of cl-PARP1, and p-H2AX performed on AMO1 and ABZB 48 h from treatment. GAPDH was used as a loading control. B. Graphical results of bio-informatic screening (cistrome.org) showing MYC binding to LIG3 promoter. C. qPCR for ch22 and LIG3 promoter performed after Chip with MYC antibody in AMO1 and ABZB and IgG controls. D. Left panel: Promoter activity of transfected LIG3 and negative CTRL promoter constructs in ABZB cells co-transfected with either siRNA-NC or MYC-siRNA. Right panel: ABZB cells were transfected with siRNA-NC or MYC-siRNA. Immunoblot of LIG3 and MYC was performed 48 h after transfection. E. Cell viability of ABZB transfected with siRNA-NC or siRNA-MYC and treated with vehicle or increasing dose of RHM for 5 days